Immunology & Autoimmune Deal Benchmarks
Deal terms for rheumatoid arthritis, lupus, IBD, psoriasis, and other autoimmune conditions. Benchmarks derived from 115 verified transactions.
115
Total Deals
$648M
Avg Upfront
6
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
44
license
36
acquisition
23
collaboration
7
option
1
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
Biogen → TJ Biopharma felzartamab | license | $100M | $850M | Jun 2026 |
Avenzo Therapeutics → Travere Therapeutics BTK inhibitor | license | $100M | $1.1B | Jun 2026 |
Everest Medicines → Travere Therapeutics civorebrutinib (EVER001) | license | $113M | $1.1B | Jun 2026 |
TJ Biopharma → Biogen felzartamab | acquisition | $100M | $850M | Apr 2026 |
Apellis Pharmaceuticals → Biogen Syfovre + Empaveli (full company acquisition) | acquisition | $5.6B | $6.0B | Mar 2026 |
Galapagos → Novartis MOR106 | license | $111M | $1.1B | Mar 2026 |
Theravance → Johnson & Johnson TD-1473 | collaboration | $100M | $1.0B | Mar 2026 |
Sino Biopharmaceutical → Sanofi rovadicitinib | license | $135M | $1.5B | Mar 2026 |
Frontier Biotechnologies Inc. → GSK plc | license | $40M | $1.0B | Feb 2026 |
Repertoire Immune Medicines → Eli Lilly and Company DECODE platform | collaboration | $85M | $1.9B | Jan 2026 |
Benchmark Your Immunology & Autoimmune Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 115 verified immunology & autoimmune transactions.
Run Immunology & Autoimmune Benchmark